ArticleBMC microbiology2026
Effect of tranexamic acid on planktonic and biofilm susceptibility of Candida albicans.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFungal periprosthetic joint infection remains a challenging complication in revision arthroplasty. Candida albicans (C. albicans) is among the most frequently reported fungal pathogens, and biofilm formation further limits antifungal efficacy. Tranexamic acid (TXA) is routinely used to reduce perioperative blood loss in arthroplasty and may come into direct contact with antifungal agents within the joint environment. However, whether TXA modifies antifungal activity against C. albicans remains unclear. This study aimed to evaluate the effect of TXA on the in vitro activity of representative antifungal agents against C. albicans under planktonic and established biofilm conditions.
resultsBaseline planktonic MICs for FLC, VRC, CAS, and AMB were 0.75, 0.5, 1, and 0.75 µg/mL, respectively. In the presence of TXA, susceptibility shifts were class-dependent: MICs for VRC and CAS decreased four-fold and two-fold, respectively, while AMB exhibited a two-fold increase and FLC remained unchanged. Established biofilms showed markedly reduced antifungal susceptibility, and TXA further altered the XTT-derived biofilm metabolic inhibition profiles. For FLC, TXA increased peak metabolic inhibition from approximately 50-55% in saline to 85-90%, with an XTT-derived MBEC₉₀ of 192 µg/mL. In contrast, TXA attenuated VRC-mediated biofilm metabolic inhibition, producing a right-shifted dose-response profile relative to saline conditions. For CAS, TXA lowered the XTT-derived activity threshold from 256 to 128 µg/mL, although the response curves converged at higher concentrations. For AMB, TXA reduced apparent biofilm activity, increasing the XTT-derived minimum biofilm eradication concentrations (MBECs) threshold from 1.5 to 12 µg/mL.
conclusionsTXA differentially modulated the apparent in vitro activity of representative antifungal agents against C. albicans in an antifungal class- and growth-state-dependent manner. The discordance between planktonic and antibiofilm responses under TXA co-exposure supports further mechanistic and translational validation in clinically relevant Candida biofilm models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.